Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. Show more

Location: 103 Carnegie Center, Princeton, NJ, 08540, United States | Website: https://www.gracetx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

41.07M

52 Wk Range

$1.75 - $4.97

Previous Close

$2.97

Open

$2.96

Volume

79,226

Day Range

$2.95 - $3.13

Enterprise Value

18.07M

Cash

20.01M

Avg Qtr Burn

-3.277M

Insider Ownership

30.28%

Institutional Own.

27.64%

Qtr Updated

06/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
GTx-104 Details Aneurysmal subarachnoid hemorrhage (aSAH)	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GTx-102 Details Ataxia-Telangiectasia	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.